Rebecca Critchley-Thorne, PhD profile page

Dr. Rebecca Critchley-Thorne serves as vice president, Research & Development at Castle Biosciences. Dr. Critchley-Thorne joined Castle in December 2021 as Vice President, R&D, Spatialomics and GI, as part of the acquisition of Cernostics Inc., where she was co-founder and chief scientific officer. She led the development of the TissueCypher computational pathology platform as well as the TissueCypher Barrett’s Esophagus test and the clinical studies supporting its use. She now oversees R&D for Castle’s commercially available tests and pipeline activities. She completed training as a postdoctoral fellow at Stanford University, where she focused on highly multiplexed analysis of biomarkers to understand mechanisms of immune dysfunction in various cancer types. She completed doctoral work in cancer immunotherapy at Imperial College and Cancer Research UK in London, UK, and earned a BS hons degree in Pharmacology from the University of Sheffield, UK. Dr. Critchley-Thorne is the author of many medical and scientific publications, a principal investigator on NIH-funded research studies, and an inventor on several of Castle Biosciences’ patents.